SCHEMBL1746731

SCHEMBL1746731

COC(=O)CCc1ccc(OC2CCc3ccccc32)cc1C

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 4/20 0.45
▸ GFRA3 O60609 2/20 0.43
▸ GFRA2 O00451 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ APOBEC3A P31941 1/20 0.41
▸ APOBEC3G Q9HC16 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ PIN1 Q13526 2/20 0.37
▸ IDO1 P14902 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ RET P07949 1/20 0.35
▸ NOX1 Q9Y5S8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744685 0.89 FFAR1 (0.52) FFAR1GFRA3GFRA2ALDH1A1HPGD
SCHEMBL1744696 0.89 FFAR1 (0.52) FFAR1GFRA3GFRA2ALDH1A1HPGD
SCHEMBL1744684 0.89 FFAR1 (0.52) FFAR1GFRA3GFRA2ALDH1A1HPGD
SCHEMBL1744692 0.83 FFAR1 (0.52) FFAR1GFRA3GFRA2ALDH1A1KMT2A
SCHEMBL1744681 0.83 FFAR1 (0.52) FFAR1GFRA3GFRA2ALDH1A1KMT2A
SCHEMBL1745225 0.83 FFAR1 (0.52) FFAR1GFRA3GFRA2ALDH1A1KMT2A
SCHEMBL1744583 0.78 GFRA3 (0.49) FFAR1GFRA3GFRA2RET
SCHEMBL1746463 0.77 FFAR1 (0.53) FFAR1ALDH1A1KMT2AMEN1IDO1
SCHEMBL1747359 0.77 FFAR1 (0.51) FFAR1GFRA3GFRA2ALDH1A1KMT2A
SCHEMBL1745194 0.76 FFAR1 (0.54) FFAR1GFRA3GFRA2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 — — EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 — — EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 — — EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 — — US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 — — US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 — — US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 — — US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 — — US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 — — US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885GFRA3 412/4885GFRA2 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback